drugset / Trial / NCT07493993
Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
Major objectives to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1/CTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.
Timeline
- Start
- 2026-06-01
- Primary completion
- 2028-05-31
- Completion
- 2030-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iparomlimab and Tuvonralimab | Unknown | 5 mg/kg | — |
| Subject | Nab-paclitaxel | Small molecule | 125 mg/m2 | — |